CN114773332B - Separation method of trans isomer of anisodamine - Google Patents
Separation method of trans isomer of anisodamine Download PDFInfo
- Publication number
- CN114773332B CN114773332B CN202210340806.XA CN202210340806A CN114773332B CN 114773332 B CN114773332 B CN 114773332B CN 202210340806 A CN202210340806 A CN 202210340806A CN 114773332 B CN114773332 B CN 114773332B
- Authority
- CN
- China
- Prior art keywords
- anisodamine
- trans
- mobile phase
- flow rate
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 title claims abstract description 125
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 title claims abstract description 111
- 238000000926 separation method Methods 0.000 title claims abstract description 38
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 title claims abstract description 29
- 238000004808 supercritical fluid chromatography Methods 0.000 claims abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000006184 cosolvent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 238000002953 preparative HPLC Methods 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 239000000178 monomer Substances 0.000 abstract description 17
- 238000001514 detection method Methods 0.000 abstract description 10
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- KMYQCELRVANQNG-YXGOVGSCSA-N Br.CN1[C@@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 Chemical compound Br.CN1[C@@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 KMYQCELRVANQNG-YXGOVGSCSA-N 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002211 ultraviolet spectrum Methods 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 description 1
- KZCXMZLEEWLBFE-UHFFFAOYSA-N (3-chloro-4-methylphenyl) carbamate Chemical compound CC1=CC=C(OC(N)=O)C=C1Cl KZCXMZLEEWLBFE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000004850 capillary HPLC Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- VEEBZCGKLLSLBA-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O.CC(C)=O VEEBZCGKLLSLBA-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/50—Conditioning of the sorbent material or stationary liquid
- G01N30/52—Physical parameters
- G01N30/54—Temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/60—Construction of the column
- G01N30/6052—Construction of the column body
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the field of medicine separation and analysis, and particularly relates to a trans isomer of anisodamine and a separation and detection method thereof. Through the combination of HPLC and supercritical chromatography, the trans-isomer of the racanisodamine can be effectively separated, and then through the creative chromatographic parameter selection in the HPLC and supercritical chromatography, the separation degree is improved, so that the purity of the finally obtained two trans-isomer monomers of the racanisodamine is high, and a foundation is laid for large-scale industrial application.
Description
Technical Field
The invention belongs to the field of medicine separation and analysis, and particularly relates to a trans isomer of anisodamine and a separation and detection method thereof.
Background
Anisodamine can compete with acetylcholine to antagonize M receptor, and can be used for treating circulatory disturbance caused by smooth muscle spasm, neuralgia, fulminant meningitis, coccoid meningitis, toxic dysentery and vasospasm. The racanisodamine is anisodamine synthesis (654-2) and contains four optical isomers with 6R,2'S, 6S,2' R, 6R,2'R, 6S and 2' S configurations. Related animal experiments prove that the 6S,2' S isomer shows the strongest pharmacological activity on the intensity of the diastolic effect of the in vitro rat trachea. Whereas the 6r,2's isomer showed the strongest pharmacological activity on the smooth muscle relaxing effect of the isolated rat small intestine. Therefore, the racanisodamine is separated into four optical isomers by chiral resolution, and the single optical isomer is used for medicine, so that the safety and effectiveness of the medicine can be greatly improved.
The existing resolution method adopts capillary electrophoresis or HPLC to realize the resolution of four optical isomers of anisodamine.
However, the existing separation method has the defects of low purity of the separated optical isomer and the like, and cannot meet the requirements of industrial mass production and marketing.
Disclosure of Invention
The invention provides a trans isomer of anisodamine and a separation and detection method thereof, which aims to solve the technical problems of low purity and the like of optical isomers after separation in the prior separation method in the background technology.
The technical scheme adopted by the invention is as follows:
The racanisodamine is anisodamine synthesis (654-2) and contains four optical isomers with 6R,2'S, 6S,2' R, 6R,2'R, 6S and 2' S configurations. The present invention defines the 6R,2'R and 6S,2' S configurations as trans anisodamine and the 6R,2'S and 6S,2' R configurations as cis anisodamine.
In one aspect, the invention provides a method for separating a trans isomer of anisodamine, comprising the following steps:
s1, canceling anisodamine, and separating by adopting dynamic preparative HPLC to obtain cis-anisodamine containing 6R,2'S and 6S,2' R and trans-anisodamine containing 6R,2'R and 6S,2' S;
S2, adjusting the pH value of the cis anisodamine and the trans anisodamine obtained in the step S1 to 8.5-10, extracting at least 1 time by using chloroform and the like in proportion, and merging the extracts to spin dry to obtain the purified cis anisodamine and the trans anisodamine;
S3, dissolving the trans-anisodamine obtained in the step S2 by using a solvent, then adopting a supercritical chromatography to split, and then carrying out spin drying to obtain the anisodamine of 6R,2'R and the anisodamine of 6S,2' S respectively, wherein the specific parameters of the supercritical chromatography are as follows:
Chromatographic column: 30 x 250mm 10 μm;
Mobile phase: one of supercritical CO 2、N2 and NH 3;
cosolvent: methanol and 0.2 percent of 7mol of NH 3, and the mass of the cosolvent is 15 to 30 percent of that of the mobile phase;
cycle time: 10-20 min;
run time: 20-30 min;
wavelength: 200-240 nm;
Back pressure: 90-110 bar;
column temperature: 30-40 ℃;
Mobile phase flow rate: 30-40 ml/min;
total flow rate: 40-50 ml/min.
The beneficial effects of the invention are as follows: through the combination of HPLC and supercritical chromatography, the resolution and extraction of the trans-isomer in anisodamine can be smoothly realized, the purity of the extracted trans-isomer monomer is higher than 99%, the purity of anisodamine hydrobromide obtained after salification is still higher than 99%, the purity requirement of the anisodamine hydrobromide can be reached and is far higher than that of Chinese pharmacopoeia, compared with the purity of the trans-isomer monomer obtained after the isomerism separation of the racemic anisodamine on the market, the quality and the safety of products are directly improved, and the technical problem in the background technology is solved. The single optical isomer is used for medication, so that the safety and effectiveness of the medication can be greatly improved.
On the basis of the technical scheme, the invention can be improved as follows.
Further, in step S3, the mobile phase is supercritical CO 2.
The adoption of the further scheme has the beneficial effects that the supercritical fluid phase condition of CO 2 can lead the separation effect of the trans isomer in the racanisodamine to be better and realize the effective separation.
Further, in step S3, the flow rate of the mobile phase is 33.75ml/min, and the mass of the cosolvent is 25% of the mobile phase.
The adoption of the further scheme has the advantages that the peak time can be shortened by proper flow rate and mass ratio of the cosolvent, and the separation of isomers of the racanisodamine can be smoothly realized.
Further, in step S3, the solvent is methanol, and the wavelength is 215nm.
The further scheme has the beneficial effects that the methanol is adopted as the solvent, so that the separation degree can be effectively improved, and the resolution of the racanisodamine is facilitated.
Further, in step S3, the column temperature was 35 ℃, the column was CHIRALCEL OX (30 x 250mm 10 μm) (Daicel), the cycle time was 13.5min, the run time was 25min, the back pressure was 100bar, and the total flow rate was 45ml/min.
The adoption of the further scheme has the beneficial effects that the implementation of the optimal parameters can ensure that the trans-isomer in the racanisodamine can be resolved smoothly, the resolution effect is good, and the quality of the product obtained after the subsequent drug synthesis by taking two trans-isomer monomers as raw materials is directly improved.
Further, in step S1, the chromatographic parameters of the separation by preparative HPLC are as follows:
chromatographic column: DAC80 dynamically prepares a separation column;
Chromatographic column packing: a Chinese spectrum LD-2-C18;
Flow rate: 150-220 ml/min;
Wavelength: 200-220 nm;
The mobile phase is a mixture of 0.1% formic acid and methanol mixed according to the mass ratio of 95:5 when the elution time is 0-45 min, and the mobile phase is a mixture of 0.1% formic acid and methanol mixed according to the mass ratio of 30:70 when the elution time is 45-60 min.
The technical scheme has the beneficial effects that the quality control can be better carried out in the splitting process, and the quality of the product obtained after splitting is improved.
Further, in step S1, the flow rate was 200ml/min and the wavelength was 210nm.
The method has the beneficial effects that the trans-isomer of the racanisodamine can be effectively separated through the combination of the HPLC and the supercritical chromatography, and then the separation degree is improved through creative chromatographic parameter selection in the HPLC and the supercritical chromatography, so that the purity of the finally obtained two trans-isomer monomers of the racanisodamine is high, and a foundation is laid for large-scale industrial application.
On the other hand, the invention also provides a method for detecting a pair of trans isomers of anisodamine, which comprises the following steps:
anisodamine of 6R,2'R or anisodamine of 6S,2' S is detected by LCMS with the following parameters:
Chromatographic column: waters X Bridge C18 column (50 mm x 4.6mm x 3.5 um);
Mobile phase: mobile phase A is NH 4HCO3 with the concentration of 0.01mol/L, and mobile phase B is acetonitrile;
The flow rate is 2mL/min, the column temperature is 40 ℃, the elution time is between 0 and 1.6min, the mobile phase B is between 5 and 95 percent, and the elution time is between 1.6 and 3min, the mobile phase B is 95 percent.
The method has the beneficial effects that the separated trans-isomer can be successfully and effectively detected by LCMS detection, the peak is smooth, and the peak shape is good.
On the other hand, the invention also provides a 6R,2' R anisodamine monomer which is prepared by adopting the separation method of the trans isomer of anisodamine.
The method has the beneficial effect that the 6R,2' R anisodamine monomer with high purity can be successfully obtained.
On the other hand, the invention also provides a 6S,2' S anisodamine monomer which is prepared by adopting the separation method of the trans isomer of anisodamine.
The invention has the beneficial effect that the 6S,2' S anisodamine monomer with high purity can be successfully obtained.
Drawings
FIG. 1 is a diagram showing resolution of cis-anisodamine and trans-anisodamine of the present invention;
FIG. 2 is a chromatogram of the invention prior to chiral resolution of trans anisodamine;
FIG. 3 is a trans-front chromatogram of the present invention;
FIG. 4 is a trans-post peak chromatogram of the present invention;
FIG. 5 is a LCMS chromatogram of anisodamine of 6R,2' R of the present invention;
FIG. 6 is a LCMS chromatogram of 6S,2' S anisodamine of the present invention;
FIG. 7 is a graph of anisodamine hydrobromide of 6R,2' R according to the present invention;
FIG. 8 is a graph of anisodamine hydrobromide of 6S,2' S of the present invention;
FIG. 9 is a graph of anisodamine ultraviolet spectra of 6R,2' R of the present invention;
FIG. 10 is a graph of the ultraviolet spectrum of anisodamine of the present invention at 6S,2' S;
FIG. 11 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 1 of the present invention;
FIG. 12 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 7 of the present invention;
FIG. 13 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 8 of the present invention;
FIG. 14 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 9 of the present invention;
FIG. 15 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 10 of the present invention;
FIG. 16 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 11 of the present invention;
FIG. 17 is a graph of anisodamine split chromatograms of 6R,2'R and 6S,2' S of example 12 of the present invention;
FIG. 18 is a structural formula of the 6R,2'S, 6S,2' R, 6R,2'R, 6S,2' S configuration of the present invention.
Detailed Description
The principles and features of the present invention are described below with reference to the drawings, the examples are illustrated for the purpose of illustrating the invention and are not to be construed as limiting the scope of the invention.
The racanisodamine is anisodamine synthesis (654-2) and contains four optical isomers with 6R,2'S, 6S,2' R, 6R,2'R, 6S and 2' S configurations. The structural formulas of the 6R,2'S, 6S,2' R, 6R,2'R, 6S,2' S configurations are shown in FIG. 18.
Example 1,
A method for separating trans isomer of anisodamine, comprising the following steps:
S1, separating 14g of racanisodamine by dynamic preparative HPLC to obtain cis-anisodamine containing 6R,2'S and 6S,2' R and trans-anisodamine containing 6R,2'R and 6S,2' S, and total 7g;
the chromatographic parameters for the separation by preparative HPLC are as follows:
chromatographic column: DAC80 dynamically prepares a separation column;
Chromatographic column packing: a Chinese spectrum LD-2-C18;
flow rate: 200ml/min;
Wavelength: 210nm;
the mobile phase is a mixture of 0.1% formic acid and methanol mixed according to the mass ratio of 95:5 when the elution time is 0-45 min, and the mobile phase is a mixture of 0.1% formic acid and methanol mixed according to the mass ratio of 30:70 when the elution time is 45-60 min. The resolution patterns of the obtained cis-anisodamine and trans-anisodamine are shown in figure 1.
S2, adjusting the pH of the mixture of the cis anisodamine and the trans anisodamine obtained in the step S1 to 9.2, extracting for 5 times by chloroform in equal proportion, and merging the extracts to spin dry to obtain 5.33g of purified cis anisodamine and 5.63g of trans anisodamine; the trans anisodamine is detected by HPLC, and the obtained chromatogram before chiral resolution is shown in figure 2, and the peak sequence is 6R,2'R and 6S,2' S in the trans isomer of the racanisodamine. Thus, as can be seen from fig. 2, the trans anisodamine contains two trans isomers, and the HPLC parameters are as follows:
chromatographic column: CHIRALCEL OX-3 (4.6100 mm) chiral chromatography column;
Mobile phase: 0.2% methanol of 7mol nh 3;
The flow rate was 2mL/min, the column temperature was 35℃and the detection wavelength was 215nm.
S3, dissolving 5.63g of trans anisodamine obtained in the step S2 with 55mL of methanol, and then resolving by adopting a supercritical chromatography to obtain a map as shown in figure 11, wherein the figure 11 shows that two monomers in a trans isomer realize effective resolution, the trans is spin-dried at 35 ℃ to respectively obtain 2.11g of anisodamine of 6R,2'R and 2.08g of anisodamine of 6S,2' S, and the specific parameters of the supercritical chromatography are as follows:
chromatographic column: CHIRALCEL OX (30 x 250mm 10 μm) (Daicel);
Mobile phase: supercritical CO 2, CO-solvent: methanol and 0.2% of 7mol NH 3; the mass of the cosolvent is 25% of that of the mobile phase;
Cycle time: 10.3min;
Run time: 20min;
Wavelength: 215nm;
Back pressure: 100bar;
Column temperature: 35 ℃;
mobile phase flow rate: 38.25ml/min;
Total flow rate: 45ml/min.
Then, anisodamine monomer with 6R,2'R is detected according to the same detection condition of HPLC in step S2, and the result is shown in figure 3, which proves that the trans-front peak in the chromatogram is anisodamine with 6R,2' R.
Then, the anisodamine monomer with 6S,2'S is detected according to the same detection condition of HPLC in the step S2, and the anisodamine with 6S,2' S as the trans-post peak in the chromatogram is proved to be shown in the figure 4.
EXAMPLE 2,
The anisodamine of 6R,2'R obtained in step S3 of example 1 was taken and detected by LCMS, the front peaks of the trans isomer of anisodamine are shown in FIG. 5, and it can be confirmed from FIG. 5 that anisodamine of 6R,2' R was successfully separated from example 1, and the parameters of LCMS are as follows:
Chromatographic column: waters X Bridge C18 column (50 mm x 4.6mm x 3.5 um);
Mobile phase: mobile phase A is NH 4HCO3 with the concentration of 0.01mol/L, and mobile phase B is acetonitrile;
The flow rate is 2mL/min, the column temperature is 40 ℃, and when the elution time is 0-1.6 min, the mobile phase B is 5-95%; when the elution time is 1.6-3 min, the mobile phase B is 95%.
EXAMPLE 3,
The 6S,2'S anisodamine obtained in step S3 of example 1 was taken and detected by LCMS, the rear peak of the trans isomer of anisodamine was shown in FIG. 6, and it can be confirmed from FIG. 6 that 6, 6S,2' S anisodamine was successfully separated in example 1, and the parameters of LCMS were as follows:
Chromatographic column: waters X Bridge C18 column (50 mm x 4.6mm x 3.5 um);
Mobile phase: mobile phase A is NH 4HCO3 with the concentration of 0.01mol/L, and mobile phase B is acetonitrile;
The flow rate is 2mL/min, the column temperature is 40 ℃, and when the elution time is 0-1.6 min, the mobile phase B is 5-95%; when the elution time is 1.6-3 min, the mobile phase B is 95%.
EXAMPLE 4,
The anisodamine monomers of 6R and 2'R and the anisodamine monomers of 6S and 2' S of the example 1 are respectively taken and respectively dissolved in absolute ethyl alcohol, hydrobromic acid is respectively dripped into salt formation, and the solubility difference of the anisodamine monomers in solvents at different temperatures is utilized to obtain hydrobromide solids.
The final 2 isomer hydrobromide salt obtained is shown in table 1 below:
TABLE 1
| Isomer designation | Trans-front peak | Trans-postpeak |
| Quality (g) | 2.1142 | 2.0810 |
| Hydrobromide mass (g) | 1.68 | 2.27 |
| Crystallization solvent | Ethanol | Acetone (acetone) |
| Melting point (crude measurement, DEG C) | 176.7～177.4 | 175.5～176.1 |
The anisodamine hydrobromide HPLC detection method is carried out according to the Chinese pharmacopoeia to obtain a 6R,2' R anisodamine hydrobromide chromatogram shown in figure 7 and a 6S,2' S anisodamine hydrobromide chromatogram shown in figure 8, and the statistics of the related substances of the 6R,2' R anisodamine hydrobromide shown in figure 7 are shown in the following table 2:
TABLE 2
Therefore, according to Table 2 and FIG. 7, the purity of 6R,2' R anisodamine after salifying is up to 99.19%, which shows that the separation method of the trans isomer of anisodamine has good separation effect and high purification degree, and is suitable for industrial production. The separation purity of the anisodamine is far higher than that of the trans anisodamine monomer obtained by the prior separation method.
According to FIG. 8, the statistics of the relevant substances for anisodamine hydrobromide at 6S,2' S are shown in Table 3 below:
TABLE 3 Table 3
| Name of the name | Impurity 1 | Impurity 2 | Impurity 3 | Impurity 4 | Impurity 5 | Impurity 6 |
| Retention time/min | 5.094 | 9.471 | 10.206 | 10.723 | 13.194 | 24.085 |
| Area percent | 0.02％ | 0.18％ | 0.07％ | 0.24％ | 0.31％ | 0.14％ |
Therefore, according to Table 3 and FIG. 8, the purity of 6S,2' S anisodamine after salifying is up to 99.04%, and the separation effect of the method for separating the trans isomer of anisodamine is good, the purification degree is high, and the method is suitable for industrial production. The separation purity of the anisodamine is far higher than that of the trans anisodamine monomer obtained by the prior separation method.
EXAMPLE 5,
The anisodamine standard of 6R,2'R is prepared into 1mg/ml solution by methanol, the solution is scanned by an ultraviolet-visible spectrophotometer, an ultraviolet spectrum is recorded, as shown in figure 9, the figure 9 shows that the anisodamine of 6R,2' R has larger absorption peak near 210nm, 215nm is selected as the detection wavelength considering the interference of the absorption of the tail end of the solvent, and the separation degree of the separation method can be effectively improved.
EXAMPLE 6,
The anisodamine standard of 6S,2'S is prepared into 1mg/ml solution by methanol, the solution is scanned by an ultraviolet-visible spectrophotometer, an ultraviolet spectrum is recorded, as shown in figure 10, it can be obtained from figure 10 that the anisodamine of 6S,2' S has a larger absorption peak near 210nm, and 215nm is selected as the detection wavelength of the invention in consideration of the interference of the absorption of the tail end of the solvent. The separation degree of the separation method can be effectively improved.
EXAMPLE 7,
The difference from example 1 is that in step S3, the mobile phase is supercritical N 2 O, and the split chromatograms of 6R,2'R anisodamine and 6S,2' S anisodamine obtained in step S3 are shown in FIG. 12, under which conditions the 6R,2'R anisodamine and 6S,2' S anisodamine could not be separated effectively.
EXAMPLE 8,
The difference from example 1 is that in step S3, the mobile phase is supercritical NH 3. The anisodamine and anisodamine resolution chromatograms of 6r,2' r and 6S,2' S obtained in step S3 are shown in fig. 13, under which the anisodamine and anisodamine of 6r,2' r cannot be effectively separated.
EXAMPLE 9,
The difference from example 1 is that in step S3, the solvent is ethanol. The anisodamine and anisodamine resolution chromatograms of 6r,2'r and 6S,2' S obtained in step S3 are shown in fig. 14, under which the anisodamine and anisodamine of 6r,2'r and 6S,2' S can be effectively separated, but peak type etc. are poor, so the separation effect is better when the solvent of example 1 is methanol, and also the separation effect of example 1 is better.
EXAMPLE 10,
The difference from example 1 is that in step S3, the column temperature was 40 ℃. The anisodamine and anisodamine split chromatograms of 6r,2'r and 6S,2' S obtained in step S3 are shown in fig. 15, under which the anisodamine and 6S,2'S base of 6r,2' r can be effectively separated but the peak shape is poor.
EXAMPLE 11,
The difference from example 1 is that in step S3 the packing of the column is OZOX, cellulose-tris (3, 5-dimethylphenylcarbamate). The anisodamine and anisodamine resolution chromatograms of 6r,2' r and 6S,2' S obtained in step S3 are shown in fig. 16, under which the anisodamine and anisodamine of 6r,2' r cannot be effectively separated.
EXAMPLE 12,
The difference from example 1 is that in step S3 the packing of the column is ODOG, cellulose-tris (3-chloro-4-methylphenyl carbamate). The anisodamine and anisodamine resolution chromatograms of 6r,2' r and 6S,2' S obtained in step S3 are shown in fig. 17, under which the anisodamine and anisodamine of 6r,2' r cannot be effectively separated.
In the description of the present specification, the terms "one embodiment," "some embodiments," "particular embodiments," and the like, mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (3)
1. A method for separating a trans isomer of anisodamine, which is characterized by comprising the following steps:
s1, canceling anisodamine, and separating by adopting dynamic preparative HPLC to obtain cis-anisodamine containing 6R,2'S and 6S,2' R and trans-anisodamine containing 6R,2'R and 6S,2' S;
the chromatographic parameters for the separation by preparative HPLC are as follows:
chromatographic column: DAC80 dynamically prepares a separation column;
Chromatographic column packing: a Chinese spectrum LD-2-C18;
Flow rate: 150-220 ml/min;
Wavelength: 200-220 nm;
When the elution time is 0-45 min, the mobile phase is a mixture of 0.1% formic acid and methanol mixed according to the mass ratio of 95:5, and when the elution time is 45-60 min, the mobile phase is a mixture of 0.1% formic acid and methanol mixed according to the mass ratio of 30:70;
S2, adjusting the pH value of the cis anisodamine and the trans anisodamine obtained in the step S1 to 8.5-10, extracting at least 1 time by using chloroform in equal proportion, merging the extracts, and spin-drying to obtain the purified cis anisodamine and trans anisodamine;
S3, dissolving the trans-anisodamine obtained in the step S2 by using a solvent, then adopting a supercritical chromatography to split, and then carrying out spin drying to obtain the anisodamine of 6R,2'R and the anisodamine of 6S,2' S respectively, wherein the specific parameters of the supercritical chromatography are as follows:
chromatographic column: CHIRALCEL OX 30 x 250mm 10 μm;
Mobile phase: supercritical CO 2;
Cosolvent: methanol and 0.2% of 7mol of NH 3, wherein the mass of the cosolvent is 15-30% of that of the mobile phase;
Cycle time: 13.5min;
Run time: 25min;
wavelength: 215nm;
back pressure: 100bar;
Column temperature: 35 ℃;
Mobile phase flow rate: 30-40 ml/min;
Total flow rate: 40-50 ml/min;
The solvent is methanol.
2. The method for separating trans isomer of anisodamine according to claim 1, wherein in step S3, the flow rate of said mobile phase is 33.75ml/min and the mass of the co-solvent is 25% of the mobile phase.
3. The method for separating trans isomer of anisodamine according to claim 1, wherein in step S1, the flow rate is 200ml/min and the wavelength is 210nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210340806.XA CN114773332B (en) | 2022-03-25 | 2022-03-25 | Separation method of trans isomer of anisodamine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210340806.XA CN114773332B (en) | 2022-03-25 | 2022-03-25 | Separation method of trans isomer of anisodamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114773332A CN114773332A (en) | 2022-07-22 |
| CN114773332B true CN114773332B (en) | 2024-06-07 |
Family
ID=82427616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210340806.XA Active CN114773332B (en) | 2022-03-25 | 2022-03-25 | Separation method of trans isomer of anisodamine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114773332B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108707148A (en) * | 2018-06-11 | 2018-10-26 | 哈尔滨医科大学 | The chiral separation method of four isomers in a kind of Racanisodamine |
-
2022
- 2022-03-25 CN CN202210340806.XA patent/CN114773332B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108707148A (en) * | 2018-06-11 | 2018-10-26 | 哈尔滨医科大学 | The chiral separation method of four isomers in a kind of Racanisodamine |
Non-Patent Citations (3)
| Title |
|---|
| 大鼠粪样中山莨菪碱及其代谢物的串联质谱法检测;陈怀侠等;《药学学报》;第41卷(第12期);1166-1169 * |
| 超临界流体色谱分离技术应用研究进展;张怡评等;《中医药导报》;第18卷(第8期);89-91 * |
| 超临界流体色谱法拆分某一生物碱类手性化合物;钟浩等;《沈阳医学院学报》;第19卷(第6期);498-504 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114773332A (en) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10759776B2 (en) | Synthesis and resolution of nicotine | |
| CN104764825B (en) | Separation and detection method for enantiomers of ezetimibe key intermediate | |
| CN106226427A (en) | A kind of supercritical fluid chromatography quickly splits the method for aranidipine racemic modification | |
| Francotte et al. | Preparative resolution of the enantiomers of Tert‐leucine derivatives by simulated moving bed chromatography | |
| CN112480028B (en) | Method for chiral resolution of promethazine | |
| CN114773332B (en) | Separation method of trans isomer of anisodamine | |
| CN106226426B (en) | A kind of method that high performance liquid chromatography splits canagliflozin five-membered ring impurity enantiomer | |
| CN114874206B (en) | Separation method of cis isomer of anisodamine | |
| CN109406685B (en) | High performance liquid chromatography method for separating carfilzomib and isomers thereof | |
| CA2465043C (en) | Novel mandelate salts of substituted tetracyclic tetrahydrofuran derivatives | |
| Yan et al. | Supercritical fluid chromatography and steady‐state recycling: Phase appropriate technologies for the resolutions of pharmaceutical intermediates in the early drug development stage | |
| CN109678752B (en) | Method for synthesizing L-2-aminobutanamide hydrochloride by asymmetric transformation | |
| US10829455B2 (en) | Methods of resolving racemic mixture to obtain (−)-Huperzine A | |
| EP1771232A1 (en) | Method for producing dimethylaminoarglabine hydrochloride | |
| CN109369590A (en) | A kind of method for separating and preparing of Nobiletin | |
| US6541631B1 (en) | Methods of separating FTC isomers and derivatives thereof | |
| US20070123533A1 (en) | New process for preparing an optically pure 2-morpholinol derivative | |
| CN111440121B (en) | Method for splitting two key intermediates in total synthesis process of optical pure tetrandrine | |
| Takahashi et al. | Separation of carnitine enantiomers as the 9-anthroylnitrile derivatives and high-performance liquid chromatographic analysis on an ovomucoid-conjugated column | |
| CN113820402A (en) | HPLC analysis method of impurity reference substance of mirabegron | |
| CN115521317A (en) | Method for preparing nafrafine intermediate | |
| CN114517215A (en) | Demethylation method of aryl methyl ether and preparation method of desvenlafaxine or salt thereof | |
| Kagel et al. | A liquid chromatographic method for the determination of the enantiomeric purity of the anticancer drug, 9-amino-20 (S)-camptothecin | |
| CN116764273A (en) | Chiral hydrogen bond organic framework material modified capillary column and application thereof | |
| CN115677546A (en) | Chiral synthesis method of D-p-methylsulfonylphenylserine ethyl ester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |